Literature DB >> 22192730

Biliary-tract cancer: improving therapy by adding molecularly targeted agents.

Lars Henrik Jensen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22192730     DOI： 10.1016/S1470-2045(11)70329-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Molecular targeted therapy for biliary tract malignancy: defining the target.

Authors:  Sarah B Fisher; Kevin E Fisher; Shishir K Maithel
Journal:  Hepatobiliary Surg Nutr       Date:  2012-12       Impact factor: 7.293

2.  Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Li Huang; Wei Chen; Peiwen Liang; Wenjie Hu; Kunsong Zhang; Shunli Shen; Jiancong Chen; Zhaohui Zhang; Bin Chen; Yuyan Han; Fanyin Meng; Sharon DeMorrow; Xiaoyu Yin; Jiaming Lai; Lijian Liang
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

3.  Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.

Authors:  Ming Zhan; Rui-Meng Yang; Hui Wang; Min He; Wei Chen; Sun-Wang Xu; Lin-Hua Yang; Qiang Liu; Man-Mei Long; Jian Wang
Journal:  Cancer Commun (Lond)       Date:  2018-07-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.